This site is intended for Healthcare professionals only.

Early screening for gestational diabetes not beneficial, Study refutes ACOG guidance


Early screening for gestational diabetes not beneficial, Study refutes ACOG guidance

In a new study, the researchers have found that early screening for gestational diabetes in obese women does not lead to better birth outcomes as compared to screening done at the routine period. The study shall be presented on February 14, 2019, at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting.

The American College of Obstetricians and Gynecologists (ACOG) recommends that all pregnant women be screened for GDM. According to ACOG, routine screening for GDM should take place at 24 to 28 weeks gestation with earlier screening (at the initial prenatal visit) in women with certain risk factors, including obesity.

According to the Centers for Disease Control and Prevention (CDC), gestational diabetes affects an estimated 2 – 10% of pregnancies in the United States. If left untreated, gestational diabetes (GDM) can lead to pregnancy complications, including preterm birth, caesarean delivery and more.

To date, however, there have been no randomized control trials (RTC) that demonstrate early screening in obese women results in improved birth outcomes.

In the study, 959 obese pregnant women were randomized into two groups. The first group was screened between 14 – 20 weeks. The second group was screened at 24 – 28 weeks. A variety of birth outcomes were examined, including the rate of cesarean delivery, shoulder dystocia, hypertension, macrosomia, neonatal hypoglycemia, neonatal hyperbilirubinemia and more.

“The only notable difference between women in the early screening group and those in the routine screening group was an increase in the use of insulin in the early screening group,” said Lorie M. Harper, MD, MSCI, lead author of the abstract and associate professor at the University of Alabama at Birmingham. While there are no significant harms associated with insulin use in pregnancy, it can be painful to inject and costly.

“Our study results suggest that early screening in obese women is not beneficial,” said Harper. “Since this the was the first of its kind, additional studies are needed to assess early screening in a large, diverse population and the best screening thresholds to use early in pregnancy.”



Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted